News|Articles|November 20, 2024

First Case of Clade I Mpox Diagnosed in the US

The person had recently traveled to areas experiencing clade I mpox virus transmission and sought medical care for mpox symptoms in the United States.

The Centers for Disease Control and Prevention’s (CDC) issued a Health Alert Network (HAN) Health Advisory to information the public that a case of clade I mpox was confirmed by the California Department of Public Health (CDPH) on November 15. This is the first case in the United States. The person had traveled to areas where clade I transmission has been ongoing.1

In terms of the person’s condition, the individual is receiving care in the US and is isolating from others. The patient, who has no underlying health conditions, has not had any severe manifestations of disease, and symptoms are improving, according to the CDC’s statement. The federal agency said it is working closely with the local and state health authorities to investigate the circumstances surrounding this case and to prevent spread of the virus. As of November 18, no additional clade I mpox cases have been reported in the country.1

Distinguishing Between Clade I and Clade II


According to the CDC, mpox has 2 distinct genetic clades: clade I (with subclades Ia and Ib), which has been endemic to some countries in Central Africa, and clade II (with subclades IIa and IIb) is historically endemic to some countries in West Africa.1

Clade I mpox has previously been observed to be more transmissible and to cause a higher proportion of severe infections than clade II MPXV.2

In a previous interview with Contagion, Carlos del Rio, MD, FIDSA, executive associate dean, Emory School of Medicine & Grady Health System, distinguished professor, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, discussed the differences between the 2 clades.

"The current mpox clade I outbreak in the DRC has already infected over 14,000 persons (mostly women and children under 15) and has caused over 500 deaths. The outbreak has now spread to other countries in Africa and there is the possibility of spread beyond the continent," said del Rio. "Clade I is more virulent and has a higher mortality than clade II (which caused the 2022 outbreak mostly among MSM [men who have sex with men]). The available JYNNEOS vaccine is effective in the prevention of mpox clade I but the challenge is not having enough vaccine available in countries that need it most."2

There have been outbreaks of clade II in the US, as previously reported by Contagion.

The Clade I Statistics

From January 1 through November 15, 2024, about 12,000 confirmed cases of clade I mpox and at least 47 deaths have been reported in Central and Eastern African countries. These countries include Burundi, Central African Republic, Democratic Republic of the Congo, Republic of the Congo, Rwanda, and Uganda. Data from affected countries indicate that a large proportion of clade I mpox cases among adults were associated with heterosexual contact. Transmission to close contacts within households, including to children, also has been reported.1

Back in August, the Africa Centers for Disease Control and Prevention (Africa CDC) has officially declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS)—the first such declaration by the agency since its inception in 2017.2

References
1. First Case of Clade I Mpox Diagnosed in the United States. CDC. November 18, 2024. Accessed November 20, 2024.
https://emergency.cdc.gov/han/2024/han00519.asp
2. Contagion Editorial Team. Africa CDC Director General: Mpox Outbreak a Public Health Emergency of Continental Security. Contagion. August 14, 2024.Accessed November 20, 2024.


Related to this article

FAQ: What You Need to Know About West Nile Virus in 2026
After 2 adults died of West Nile virus in central North Carolina this month, this FAQ explains how the mosquito-borne virus spreads, who faces the greatest risk of severe neuroinvasive disease, and how clinicians can diagnose, manage, and help prevent infection when no vaccine or antiviral treatment exists.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.